New Data Reinforce Benefits Of Bristol Myers's Opdivo In Earlier Stages Of Melanoma

  • Bristol Myers Squibb Co BMY announced results from the Phase 3 CheckMate -76K trial evaluating adjuvant Opdivo (nivolumab) for up to 12 months versus placebo in 790 patients with completely resected stage IIB or IIC melanoma.
  • Opdivo as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo. 
  • Opdivo reduced the risk of recurrence or death by 58% versus placebo. Twelve-month RFS rates for Opdivo were 89% versus 79% for placebo. 
  • Related: Bristol Myers' Opdivo Combo Treatment Scores European Approval For Skin Cancer Setting.
  • The RFS benefit was observed across predefined subgroups in the trial, including the T category and disease stage. 
  • Twelve-month RFS rates by stage for patients who received Opdivo were 93% in stage IIB (versus 84% in placebo) and 84% in stage IIC (versus 72% with placebo).
  • The safety profile of Opdivo was consistent with that seen in previously reported studies, and no new safety signals were observed at the time of the analysis. 
  • Grade 3/4 treatment-related adverse events (TRAEs) were 10% in the Opdivo arm and 2% in the placebo arm. 
  • TRAE-related discontinuation was 15% for those in the Opdivo arm and 3% for those in the placebo arm.
  • Price Action: BMY shares closed 0.84% down at $71.74 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!